Cellectis Romainvil (CMVLF) 27.9000 $CMVLF
Cellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL)
BusinessWire - Mon Jun 20, 4:01PM CDT
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis S.A. Reports Results from Shareholders' General Meeting Held on May 17, 2016
BusinessWire - Thu May 19, 4:00PM CDT
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis Reports First Quarter 2016 Financial Results
BusinessWire - Wed May 11, 4:00PM CDT
--- Secured strategic supply of key materials for GMP manufacturing
CLLS: 26.51 (+0.61)
Cellectis to Present Data on Its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting
BusinessWire - Mon May 02, 4:00PM CDT
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis Announces RetroNectin(R) Supply and License Agreement with Takara Bio Inc.
BusinessWire - Mon Mar 21, 4:00PM CDT
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis and MabQuest Announce Immunotherapy Partnership on New Class of PD-1 Antagonist Monoclonal Antibodies
BusinessWire - Wed Mar 16, 4:00PM CDT
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis Reports Fourth Quarter and Full Year 2015 Financial Results
BusinessWire - Mon Mar 14, 4:19PM CDT
--- Encouraging data from the First-in-Human compassionate use of UCART19
CLLS: 26.51 (+0.61)
Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 79.28 (+0.22), BIOD: 0.40 (+0.01), CLBS: 5.31 (-0.14), ARGS: 4.25 (unch), AZN: 33.90 (+0.34), CGEN: 6.98 (-0.01), ATHX: 2.00 (-0.01)
Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H2 2015
M2 - Thu Feb 04, 9:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/fxbk98/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Lymphocytic Leukemia (CLL) Overview - Therapeutics Development - Pipeline Products for Chronic Lymphocytic Leukemia (CLL) - Overview - Pipeline Products for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis - Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies - Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes - Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies - Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes - Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development (Partial List) - 4SC AG - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Aprogen, Inc. - Arno Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Bayer AG - BeiGene(Beijing) Co.,Ltd - Bellicum Pharmaceuticals, Inc. - Biogen, Inc. - BioInvent International AB - Bionovis SA - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Coherus BioSciences, Inc. - CTI BioPharma Corp. - Cyclacel Pharmaceuticals, Inc. - Eli Lilly and Company - Emergent BioSolutions Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Genor BioPharma Co., Ltd. - Gilead Sciences, Inc. - Grupo Ferrer Internacional, S.A. - Hospira, Inc. - Hutchison MediPharma Limited For more information visit http://www.researchandmarkets.com/research/fxbk98/chronic
EBS: 27.81 (-0.20), AMGN: 174.24 (+0.62), LLY: 79.28 (+0.22), CTIC: 0.35 (unch), BMY: 59.14 (-0.15), CHRS: 29.90 (-0.61), CYCC: 8.32 (+1.39), BLCM: 18.54 (+0.42), GILD: 81.02 (+0.02), AZN: 33.90 (+0.34), ABBV: 67.25 (+0.15), CBMG: 14.04 (-0.03), CELGZ: 1.17 (+0.06)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/trfcb9/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview - Therapeutics Development - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Atara Biotherapeutics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - Bio-Path Holdings, Inc. - BioSight Ltd. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Cantargia AB - Celator Pharmaceuticals, Inc. - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Ceronco Biosciences - Constellation Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - DiNonA Inc. - Effimune SAS - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - EpiZyme, Inc. - Erytech Pharma SA - Eureka Therapeutics, Inc. - Fate Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - GlaxoSmithKline Plc - Hangzhou Minsheng Pharmaceutical Group Co.,Ltd For more information visit http://www.researchandmarkets.com/research/tr...ymphocytic
FATE: 2.87 (-0.05), AMGN: 174.24 (+0.62), EPZM: 8.25 (+0.09), LLY: 79.28 (+0.22), ATRA: 22.43 (+0.10), GSK: 44.21 (+0.05), BMY: 59.14 (-0.15), ATNM: 1.68 (+0.05), CYCC: 8.32 (+1.39), BLCM: 18.54 (+0.42), BPTH: 1.66 (+0.02), CALA: 3.30 (-0.01), ABBV: 67.25 (+0.15), BXLT: 46.02 (-0.18), CBMG: 14.04 (-0.03)
Cellectis Enters into New Agreement with CELLforCURE for the cGMP Manufacturing of UCART123 for Hematological Malignancies
BusinessWire - Tue Jan 19, 4:00PM CST
Regulatory News:
CLLS: 26.51 (+0.61)
Global CRISPR Market 2015-2021: Market for CRISPR Technology is Niche
M2 - Fri Jan 15, 5:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/44hxbj/global_crispr) has announced the addition of the "Global CRISPR Market, By Country (United States, Canada, India, China, Japan, United Kingdom), Company Profiles, Share, Trends, Analysis, Opportunities, Segmentation And Forecast 2015 - 2021" report to their offering. The market is expected to grow at a CAGR of 43% from 2015 to 2021. This is driven by the fact that CRISPR is a new technology which is simple, more efficient and cost effective as compared to its peers. High adoption both in biotech and pharma industry along with high level of research is also responsible for high growth rate. The market for CRISPR technology is niche. The number of companies are still very less and most of the companies are start-ups which are going through rounds of funding. Most of the companies are working on developing CRISPR products along with the approval and commercialization of such products. These companies have successfully attracted major investments from big VC firms and companies such as Google and DuPont. These companies are relying on the disruptive nature of the technology. CRISPR has the capability to open new markets for gene surgery and genetically modified organisms. However, there are major concerns from the scientific community regarding the misuse of such technology in human cloning. Geographically North America leads the market race followed by Europe and Asia Pacific. Key Topics Covered: 1. Executive Summary 2. Market Overview 3. Sector Analysis 4. Market Determinants 5. Market Segmentation 6. Geographical Analysis 7. Company Profiling - Thermo Fisher Scientific - Editas Medicine - Caribou Biosciences - CRISPR therapeutics - Intellia - Cellectis - Horizon discovery PLC - Sigma Aldrich - Precision biosciences - GenScript - Sangamo Biosciences Inc. - Lonza group limited - Integrated DNA technologies - New England Biolabs - Oregene Technologies - Transposgen Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/44...bal_crispr
SGMO: 4.32 (-0.07)
Cellectis Announces a New CAR Architecture Controlling CAR T-Cell Functions
BusinessWire - Mon Jan 11, 4:00PM CST
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis Announces Chief Medical Officer Appointment to Senior Leadership Team
BusinessWire - Thu Jan 07, 4:30PM CST
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies
BusinessWire - Wed Dec 23, 4:00PM CST
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, January 11 - 14, 2016
BusinessWire - Mon Dec 21, 4:00PM CST
Regulatory News:
JPM: 65.85 (-0.01), CLLS: 26.51 (+0.61)
Research and Markets: Cellectis S.A. Product Pipeline Review 2015 - Analysis & Technologies
BusinessWire - Thu Dec 17, 11:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/vj9r3z/cellectis_s_a) has announced the addition of the "Cellectis S.A. - Product Pipeline Review - 2015" company profile to their offering.
Cellectis S.A. Product Pipeline Review 2015 - Analysis & Technologies
M2 - Thu Dec 17, 10:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/cltv2h/cellectis_s_a) has announced the addition of the "Cellectis S.A. - Product Pipeline Review - 2015" company profile to their offering. This report provides comprehensive information on the current therapeutic developmental pipeline of Cellectis S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - The report provides brief overview of Cellectis S.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Cellectis S.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio Benefits of this Report: - Evaluate Cellectis S.A.'s strategic position with total access to detailed information on its product pipeline - Identify new drug targets and therapeutic classes in the Cellectis S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Cellectis S.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cellectis S.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope For more information visit http://www.researchandmarkets.com/research/cl...lectis_s_a
Cellectis Announces Conference Call to Discuss UCART19 Development Collaboration with Pfizer and Servier
BusinessWire - Thu Dec 03, 4:30PM CST
Regulatory News:
PFE: 34.94 (-0.04), CLLS: 26.51 (+0.61)
Cellectis Announces Presentations at Upcoming Conferences
BusinessWire - Mon Nov 30, 4:00PM CST
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL)
BusinessWire - Mon Jun 20, 4:01PM CDT
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis S.A. Reports Results from Shareholders' General Meeting Held on May 17, 2016
BusinessWire - Thu May 19, 4:00PM CDT
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis Reports First Quarter 2016 Financial Results
BusinessWire - Wed May 11, 4:00PM CDT
--- Secured strategic supply of key materials for GMP manufacturing
CLLS: 26.51 (+0.61)
Cellectis to Present Data on Its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting
BusinessWire - Mon May 02, 4:00PM CDT
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis Announces RetroNectin(R) Supply and License Agreement with Takara Bio Inc.
BusinessWire - Mon Mar 21, 4:00PM CDT
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis and MabQuest Announce Immunotherapy Partnership on New Class of PD-1 Antagonist Monoclonal Antibodies
BusinessWire - Wed Mar 16, 4:00PM CDT
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis Reports Fourth Quarter and Full Year 2015 Financial Results
BusinessWire - Mon Mar 14, 4:19PM CDT
--- Encouraging data from the First-in-Human compassionate use of UCART19
CLLS: 26.51 (+0.61)
Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 79.28 (+0.22), BIOD: 0.40 (+0.01), CLBS: 5.31 (-0.14), ARGS: 4.25 (unch), AZN: 33.90 (+0.34), CGEN: 6.98 (-0.01), ATHX: 2.00 (-0.01)
Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H2 2015
M2 - Thu Feb 04, 9:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/fxbk98/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Lymphocytic Leukemia (CLL) Overview - Therapeutics Development - Pipeline Products for Chronic Lymphocytic Leukemia (CLL) - Overview - Pipeline Products for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis - Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies - Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes - Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies - Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes - Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development (Partial List) - 4SC AG - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Aprogen, Inc. - Arno Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Bayer AG - BeiGene(Beijing) Co.,Ltd - Bellicum Pharmaceuticals, Inc. - Biogen, Inc. - BioInvent International AB - Bionovis SA - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Coherus BioSciences, Inc. - CTI BioPharma Corp. - Cyclacel Pharmaceuticals, Inc. - Eli Lilly and Company - Emergent BioSolutions Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Genor BioPharma Co., Ltd. - Gilead Sciences, Inc. - Grupo Ferrer Internacional, S.A. - Hospira, Inc. - Hutchison MediPharma Limited For more information visit http://www.researchandmarkets.com/research/fxbk98/chronic
EBS: 27.81 (-0.20), AMGN: 174.24 (+0.62), LLY: 79.28 (+0.22), CTIC: 0.35 (unch), BMY: 59.14 (-0.15), CHRS: 29.90 (-0.61), CYCC: 8.32 (+1.39), BLCM: 18.54 (+0.42), GILD: 81.02 (+0.02), AZN: 33.90 (+0.34), ABBV: 67.25 (+0.15), CBMG: 14.04 (-0.03), CELGZ: 1.17 (+0.06)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/trfcb9/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview - Therapeutics Development - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Atara Biotherapeutics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - Bio-Path Holdings, Inc. - BioSight Ltd. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Cantargia AB - Celator Pharmaceuticals, Inc. - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Ceronco Biosciences - Constellation Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - DiNonA Inc. - Effimune SAS - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - EpiZyme, Inc. - Erytech Pharma SA - Eureka Therapeutics, Inc. - Fate Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - GlaxoSmithKline Plc - Hangzhou Minsheng Pharmaceutical Group Co.,Ltd For more information visit http://www.researchandmarkets.com/research/tr...ymphocytic
FATE: 2.87 (-0.05), AMGN: 174.24 (+0.62), EPZM: 8.25 (+0.09), LLY: 79.28 (+0.22), ATRA: 22.43 (+0.10), GSK: 44.21 (+0.05), BMY: 59.14 (-0.15), ATNM: 1.68 (+0.05), CYCC: 8.32 (+1.39), BLCM: 18.54 (+0.42), BPTH: 1.66 (+0.02), CALA: 3.30 (-0.01), ABBV: 67.25 (+0.15), BXLT: 46.02 (-0.18), CBMG: 14.04 (-0.03)
Cellectis Enters into New Agreement with CELLforCURE for the cGMP Manufacturing of UCART123 for Hematological Malignancies
BusinessWire - Tue Jan 19, 4:00PM CST
Regulatory News:
CLLS: 26.51 (+0.61)
Global CRISPR Market 2015-2021: Market for CRISPR Technology is Niche
M2 - Fri Jan 15, 5:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/44hxbj/global_crispr) has announced the addition of the "Global CRISPR Market, By Country (United States, Canada, India, China, Japan, United Kingdom), Company Profiles, Share, Trends, Analysis, Opportunities, Segmentation And Forecast 2015 - 2021" report to their offering. The market is expected to grow at a CAGR of 43% from 2015 to 2021. This is driven by the fact that CRISPR is a new technology which is simple, more efficient and cost effective as compared to its peers. High adoption both in biotech and pharma industry along with high level of research is also responsible for high growth rate. The market for CRISPR technology is niche. The number of companies are still very less and most of the companies are start-ups which are going through rounds of funding. Most of the companies are working on developing CRISPR products along with the approval and commercialization of such products. These companies have successfully attracted major investments from big VC firms and companies such as Google and DuPont. These companies are relying on the disruptive nature of the technology. CRISPR has the capability to open new markets for gene surgery and genetically modified organisms. However, there are major concerns from the scientific community regarding the misuse of such technology in human cloning. Geographically North America leads the market race followed by Europe and Asia Pacific. Key Topics Covered: 1. Executive Summary 2. Market Overview 3. Sector Analysis 4. Market Determinants 5. Market Segmentation 6. Geographical Analysis 7. Company Profiling - Thermo Fisher Scientific - Editas Medicine - Caribou Biosciences - CRISPR therapeutics - Intellia - Cellectis - Horizon discovery PLC - Sigma Aldrich - Precision biosciences - GenScript - Sangamo Biosciences Inc. - Lonza group limited - Integrated DNA technologies - New England Biolabs - Oregene Technologies - Transposgen Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/44...bal_crispr
SGMO: 4.32 (-0.07)
Cellectis Announces a New CAR Architecture Controlling CAR T-Cell Functions
BusinessWire - Mon Jan 11, 4:00PM CST
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis Announces Chief Medical Officer Appointment to Senior Leadership Team
BusinessWire - Thu Jan 07, 4:30PM CST
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies
BusinessWire - Wed Dec 23, 4:00PM CST
Regulatory News:
CLLS: 26.51 (+0.61)
Cellectis Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, January 11 - 14, 2016
BusinessWire - Mon Dec 21, 4:00PM CST
Regulatory News:
JPM: 65.85 (-0.01), CLLS: 26.51 (+0.61)
Research and Markets: Cellectis S.A. Product Pipeline Review 2015 - Analysis & Technologies
BusinessWire - Thu Dec 17, 11:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/vj9r3z/cellectis_s_a) has announced the addition of the "Cellectis S.A. - Product Pipeline Review - 2015" company profile to their offering.
Cellectis S.A. Product Pipeline Review 2015 - Analysis & Technologies
M2 - Thu Dec 17, 10:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/cltv2h/cellectis_s_a) has announced the addition of the "Cellectis S.A. - Product Pipeline Review - 2015" company profile to their offering. This report provides comprehensive information on the current therapeutic developmental pipeline of Cellectis S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - The report provides brief overview of Cellectis S.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Cellectis S.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio Benefits of this Report: - Evaluate Cellectis S.A.'s strategic position with total access to detailed information on its product pipeline - Identify new drug targets and therapeutic classes in the Cellectis S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Cellectis S.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cellectis S.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope For more information visit http://www.researchandmarkets.com/research/cl...lectis_s_a
Cellectis Announces Conference Call to Discuss UCART19 Development Collaboration with Pfizer and Servier
BusinessWire - Thu Dec 03, 4:30PM CST
Regulatory News:
PFE: 34.94 (-0.04), CLLS: 26.51 (+0.61)
Cellectis Announces Presentations at Upcoming Conferences
BusinessWire - Mon Nov 30, 4:00PM CST
Regulatory News:
CLLS: 26.51 (+0.61)
